Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma/ Brain Tumor

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Back to Current Clinical Trials

Protocol

PBTC29: Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma/ Brain Tumor

Diseases

Brain Tumor : Gliomas

Description

Low grade gliomas are among the most common primary CNS (central nervous system) neoplasms (an abnormal new mass of tissue that serves no purpose) of childhood.

Low-grade gliomas are also classified according to the location of the brain from which they originate. The commonly used therapies are surgery, chemotherapy and radiation. This study will determine the maximum tolerated dose of drug called AZD6244 (selumetinib) in children 12 years or over with gliomas which have returned following radiation and /or chemotherapy.The duration of the study will be four and half years.

Objectives

To describe the toxicity profile and define the dose limiting toxicity of AZD6244 in children with recurrent or refractory low-grade glioma.

Eligibility

Inclusion Criteria

Participant is ≥ 3 but ≤ 21 years of age at registration.
Participant has a diagnosis of low grade glioma (Grades I & II) or optic pathway gliomas with clinical and/or radiographic evidence of progression.
Participant must be able to swallow capsules.
Participant has received prior radiation therapy to treat the brain tumor and has recovered from prior chemotherapy.
Participant meets other requirements defined in the eligibility portion of the study.
Participant is able to perform ordinary tasks and daily activities as defined in the study guidelines.

For current eligibility status of this clinical study, the referring physician and/ or patient’s family may contact St. Jude’s Brain Tumor Coordinator at (901) 595-2544 or (901) 595-4599.

Contact

Ibrahim Qaddoumi, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Phone: 901-595-2365
Email: Ibrahim.qaddoumi@stjude.org

Tabatha E. Doyle, RN
Coordinator, Brain Tumor Program
Phone: 901-595-2544
Fax: 901-595-5353
Email: tabatha.doyle@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article